Rev Invest Clin
-
Randomized Controlled Trial Multicenter Study
METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2.
There is no pharmacological intervention on the treatment of hypoxemia and respiratory distress in COVID-19 patients. ⋯ The addition of MB to the treatment protocols significantly improved SpO2 and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality. ClinicalTrials.gov: NCT04370288.